Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin B in the treatment of fungal infections in cancer patients: A review

International Journal of Infectious Diseases

Volumn 3, Issue 2, 1999, Pages 109-118

  Viscoli, Claudio ^a   Castagnola, Elio ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

Cancer; Drug resistance; Emerging fungal pathogens; Invasive fungal infections; Lipid formulations of amphotericin B

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; ITRACONAZOLE;

ASPERGILLOSIS; ASPERGILLUS; CANCER PATIENT; CANDIDA; CANDIDIASIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RESISTANCE; DRUG TISSUE LEVEL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MYCOSIS; NEPHROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW;

EID: 0032442780     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(99)90019-X     Document Type: Review

References (73)

1. Crawford SW. Bone-marrow transplantation and related infections. Semin Respir Infect 1993; 8:183-190.
2. Wingard R. Changes in the spectrum of fungal infections in bone marrow transplant patients. Infect Dis Clin Pract 1994; 3:S83-S89.
3. Walsh TJ, Lyman TA. New antifungal compounds and strategies for treatment of invasive fungal infections in patients with neoplastic diseases. In: Klastersky J, ed. Infectious complications of cancer. Boston, Dordrecht, London: Kluwer Academic Publisher, 1995:113-148.
4. Meyers JD. Fungal infections in bone marrow transplant patients. Semin Oncol 1990; 17:10-13.
5. Abi-Said D, Anaissie E. New emerging fungal pathogens. Baillieres Clin Infect Dis 1995; 2:71-87.
6. Viscoli C, Castagnola E, Machetti M. Antifungal treatment in patients with cancer. J Intern Med 1997; 242:89-94.
7. Beck-Sagué CM, Jarvis WR, National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States. 1980-1990. J Infect Dis 1993; 167:1247-1251.
8. Groll A, Shah PM, Mentzel C, et al. Trends in the post-mortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33:23-32.
9. Morrison VA, Haake RJ, Weisdorf DJ. The spectrum of non-Candida fungal infections following bone marrow transplantation. Medicine 1993; 72:78-89.
10. Walsh TJ, Hiemenz J, Pizzo PA. Editorial response: evolving risk factors for invasive fungal infections: all neutropenic patients are not the same. Clin Infect Dis 1994; 18:793-798.
11. Viscoli C, Castagnola E. Factors predisposing cancer patients to infection. In: Klastersky J, ed. Infectious complications of cancer. Boston, Dordrecht, London: Kluwer Academic Publisher, 1995:1-30.
12. Wingard JR. Importance of Candida species other than Candida albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20:115-125.
13. Nguyen MH, Peacock JEJ, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100:617-623.
14. Viscoli C, Castagnola E, Van Lint MT, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective, and randomised clinical trial. Eur J Cancer 1996; 32:814-820.
15. Viscoli C, Girmenia C, Marines A, et al. An EORTC prospective, multicenter, surveillance study of candidemia in cancer patients. Clin Infect Dis 1999, in press.
16. Abi-Said D, Anaissie E, Uzun O, et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24:1122-1128.
17. Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325:1274-1277.
18. Wingard JR, Merz WG, Rinaldi MG, et al. Association of Torulopsis glabrata infection with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993; 37:1847-1849.
19. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118:495-503.
20. Goodman JL, Winston DJ, Greenfeld RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-851.
21. Kunova A, Trupl J, Dluholucky S, Galova G, Krcmery V. Use of fluconazole is not associated with a higher incidence of Candida krusei and other non-albicans Candida species. Clin Infect Dis 1995; 21:226-227.
22. White MH, Anaissie EJ, Kusne S, et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997; 24:635-642.
23. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis 1990; 12:1147-1201.
24. Viscoli C, Boni L, Etzioni R, Seidel K, Anasetti C. Infections in recipients of bone marrow transplant (BMT) from unrelated donors. Presented at the 8th International Symposium on Infections in the Immunocompromised Host, Davos, Switzerland, June 19-22, 1994.
25. Gamis AS, Gudnason T, Giebink GS, Ramsay NKC. Disseminated infection with Fusarium in recipients of bone marrow transplants. Rev Infect Dis 1991; 13:1077-1088.
26. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39:1-8.
27. Rex JH, Bennet JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331:1325-1330.
28. Rex J, Pfaller M, Barry A, Nelson PW, Webb CD. Antifungal susceptibility testing of isolates from a randomized multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob Agents Chemother 1995; 39:40-44.
29. Vanden-Bossche H, Warnock DW, Dupont B, et al. Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Mycol 1994; 32:189-202.
30. Gorbach SL. Antimicrobial resistance in the 1990s. Infect Dis Clin Pract 1996; 5:S32-S36.
31. Walsh TJ. Evolving patterns of nosocomial and community-acquired deep mycoses: analogies to other infections and implications for practitioners. Infect Dis Clin Pract 1994; 3:S103-S112.
32. Van't Wout JW. Fungal infections and antifungal drugs: Has the age of antifungal resistance dawned? Curr Opin Infect Dis 1996; 9:63-66.
33. Lam HH, Althaus BL. Antifungal prophylaxis in bone marrow transplant. Ann Pharmacother 1995; 29:921-924.
34. Marr KA, White TC, van Burik JAH, Bowden RA. Development of fluconazole resistance in Candida albicans causing disseminated infection in patients undergoing marrow transplantation. Clin Infect Dis 1997; 25:908-910.
35. Odds FC. Resistance of yeasts to azole-derivative antifungals. J Antimicrob Chemother 1993; 31:463-471.
36. Francis P, Walsh TJ. The evolving role of flucytosine in immunocompromised patients: new insight into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992; 15:1003-1018.
37. DeMuri GP, Hostetter MK. Resistance to antifungal agents. Pediatr Clin North Am 1995; 42:665-685.
38. Scholer HJ, Polak A. Resistance to systemic antifungal agents. In: Bryan LE, ed. Antimicrobial drug resistance. Orlando, Florida: Academic Press, 1984:393-460.
39. Iwata K. Drug resistance in human pathogenic fungi. Eur J Epidemiol 1992; 8:407-421.
40. Pfaller MA, Messer SA, Hollis RJ. Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae. Diagn Microbiol Infect Dis 1994; 20:127-133.
41. Persat F, Marzullo C, Guyotat D, Rochet RJ, Piens MA. Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. Eur J Cancer 1992; 28:838-840.
42. Rex JH. Editorial response: catheters and candidemia. Clin Infect Dis 1996; 22:467-470.
43. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12:308-329.
44. Glaser V. Liposomal antifungals battle for market share. Biotechnology 1995; 13:728-729.
45. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27:603-618.
46. White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998; 27:296-302.
47. Tang CM, Bowler ICJW. Do the new lipid formulations of amphotericin B really work? Clin Microbiol Infect 1997; 3:283-288.
48. Van Burik JH, Bowden RA. Standard antifungal treatment, including role of alternative modalities to administer amphotericin. Baillieres Clin Infect Dis 1995; 2:89-109.
49. Ayestarán A, López RM, Montoro JB, et al. Pharmacokinetics of conventional formulations versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia. Antimicrob Agents Chemother 1996; 40:609-612.
50. Hiemenz JW; Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996; 22:8133-8144.
51. Groll A, Girl N, Gonzalez C, et al. Penetration of lipid formulations of amphotericin B into cerebrospinal fluid and brain tissue. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Sept 28-Oct 1, 1997.
52. Clemons KV, Stevens DA. Comparison of Fungizone, Amphotec, AmBisome and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob Agents Chemother 1998; 42:899-902.
53. Lister J. Amphotericin B lipid complex (Abelcet®) in the treatment of invasive mycoses: the North American experience. Eur J Haematol 1996; 56:18-23.
54. Kline S, Larsen TA, Fieber L, et al. Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex. Clin Infect Dis 1995; 21:1154-1158.
55. Adler-Moore JP, Proffitt RT. Development, characterization, efficacy and mode of action of AmBisome®, a unilamellar liposomal formulation of amphotericin B. J Lipid Res 1993; 3:429-450.
56. Meunier F, Prentice HG, Ringden OL. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother 1991; 28:83-91.
57. Mills W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994; 86:754-760.
58. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treat-ment of invasive mycoses. Clin Infect Dis 1995; 21:1145-1153.
59. Walsh TJ, Hiemenz JW, Seibel N, Anaissie EJ. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26:1383-1396.
60. Ringden O, Jonsson V, Hansen M, Tollemar J, Jacobsen N. Severe and common side effects of amphotericin B lipid complex (Abelcet). Bone Marrow Transplant 1998; 22:733-734.
61. Wingard JR. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant 1997; 19:343-347.
62. Anaissie EJ, White MH, Uzun O, et al. Abelcet® (amphotericin B lipid complex) vs. amphotericin B for treatment of invasive candidiasis: a prospective, randomised multicentre trial. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Sept 17-20, 1995.
63. Walsh TJ, Whitcomb P, Piscitelli S, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997; 41:1944-1948.
64. Mehta J, Kelsey S, Chu P, et al. Amphotericin B lipid complex for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies. Bone Marrow Transplant 1997; 20:39-43.
65. Lister J. Amphotericin B lipid complex in the management of serious systemic mycoses in patients intolerant to amphotericin B therapy [Abstract]. Blood 1994; 84:306.
66. Ringden O, Meunier F, Tollemar J, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991; 28:73-82.
67. Chopra R, Blair S, Strang J, et al. Liposomal amphotericin B (AmBisome) in the treatment of fungal infection in neutropenic patients. J Antimicrob Chemother 1991; 28:93-104.
68. International Antimicrobial Therapy Cooperative Group E. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86:668-672.
69. Winston DJ, Hathorn J, Schuster M. Fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients: results of a randomized multicentre trial. Presented at the 20th meeting of the International Congress of Chemotherapy. Sydney, Australia, June 29-July 3, 1997.
70. Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98:711-718.
71. Walsh T, Bodensteiner J, Hiemenz S, et al. A randomized, double-blind trial of AmBisome (liposomal amphotericin B) versus amphotericin B in the empirical treatment of persistently febrile neutropenic patients. Presented at the 37th Inter-science Conference on Antimicrobial Agents and Chemotherapy, Toronto, Sept 28-Oct 1, 1997.
72. British Medical Association. British National Formulary. London: Royal Pharmaceutical Society of Great Britain, 1996.
73. Marini L, ed; Organizzazione Editoriale Medico Farmaceutica, Milan, Italy. Italian Directory of Drugs and Manufacturers, 1998.